1. Signaling Pathways
  2. Stem Cell/Wnt
  3. Wnt

Wnt

The Wnt signaling pathways are a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three Wnt signaling pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the protein Dishevelled inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell, and the noncanonical Wnt/calcium pathway regulates calcium inside the cell. The clinical importance of Wnt signaling pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-136541
    YB-0158
    Inhibitor 99.49%
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities.
    YB-0158
  • HY-170496
    Fluc-IN-1
    Inhibitor 98.44%
    Fluc-IN-1 (Compound 3) is an inhibitor for firefly luciferase with an IC50 of 25 nM. Fluc-IN-1 inhibits WNT/β-catenin signaling pathway with an IC50 of 33 nM (measuring by TOPFlash assay).
    Fluc-IN-1
  • HY-18006
    NKP608
    Inhibitor 99.88%
    NKP608 is a non-peptidic derivative of 4-aminopiperidine, a highly selective, orally active, neurokinin-1 (NK1) receptor antagonist with IC50 of 2.6 nM. NKP608 is active both in vitro and in vivo, showing extremely low affinity for NK2, NK3 receptors. NKP608 exerts its effects by blocking the NK₁ receptor, regulate cell proliferation and apoptosis, affect neurotransmitter functions and gastric mucosal repair mechanisms, and suppress the Wnt/β-catenin pathway in antitumor research. NKP608 is applicable to research related to various diseases, including cough, anxiety disorders, depression, gastric mucosal injury, and colorectal cancer.
    NKP608
  • HY-117002
    SRI 37892
    Inhibitor 99.28%
    SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents .
    SRI 37892
  • HY-P990250
    Anti-Mouse DKK3 Antibody (DKK3-4.22)
    Anti-Mouse DKK3 Antibody (DKK3-4.22) is an anti-mouse DKK3 IgG1 monoclonal antibody. Anti-Mouse DKK3 Antibody (DKK3-4.22) can improve kidney function and increases T cell infiltration. Anti-Mouse DKK3 Antibody (DKK3-4.22) can reduce skin inflammation by blocking the immunosuppressive function of DKK3. Anti-Mouse DKK3 Antibody (DKK3-4.22) can be used for researches on inflammation conditions such as unilateral ureteral obstruction (UUO) and experimental autoimmune encephalomyelitis (EAE).
    Anti-Mouse DKK3 Antibody (DKK3-4.22)
  • HY-D1474
    WNT7A-IN-1 sodium
    Inhibitor 98.05%
    WNT7A-IN-1 sodium (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region.
    WNT7A-IN-1 sodium
  • HY-112591
    NSC260594
    Inhibitor
    NSC260594 induces Apoptosis. NSC260594 binds the shallow groove of the Mcl-1 protein, and inhibits Mcl-1 expression through down-regulation of Wnt signaling proteins. NSC260594 can also recognize G9-G10-A11-G12 RNA tetraloop of HIV and prevent the binding of the Gag protein within the 5’-UTR. NSC260594 inhibits tumor growth, and can be used for research of Triple-negative breast cancers (TNBCs).
    NSC260594
  • HY-172171
    GSK3β-IN-2
    Activator 98.75%
    GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC50 of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model.
    GSK3β-IN-2
  • HY-142689
    Carboxylesterase-IN-3
    98.27%
    Carboxylesterase-IN-3 (compound 4y) is a potent inhibitor of Carboxylesterase Notum with an IC50 less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Carboxylesterase-IN-3 has the potential for the research of cancer disease.
    Carboxylesterase-IN-3
  • HY-N0899
    Wilforine
    Inhibitor 99.47%
    Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome.
    Wilforine
  • HY-108439
    Neurodazine
    Activator 99.0%
    Neurodazine is a neurogenic inducer, serve as a promoter of neurogenesisin pluripotent cells. Neurodazine promotes neurogenesis by activating Wnt and Shh signaling pathways..
    Neurodazine
  • HY-P1454A
    Fz7-21 TFA
    Antagonist 98.12%
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids.
    Fz7-21 TFA
  • HY-162520
    DJ-1-IN-1
    Inhibitor 98.60%
    DJ-1-IN-1 (compound 797780-71-3) is a DJ-1 inhibitor. DJ-1-IN-1 exhibits antiproliferative activity in ACHN cells with an IC50 value of 12.18 μM and can inhibit the Wnt signaling pathway. DJ-1-IN-1 can be used in cancer research.
    DJ-1-IN-1
  • HY-156095
    F7H
    Inhibitor 99.42%
    F7H is a Frizzled receptor FZD7 antagonist (IC50: 1.25 μM). Frizzled receptors (FZDs) influence Wnt signaling, mediating embryonic development and tissue homeostasis. F7H is a potent ligand for the FZD7 transmembrane domain (TMD).
    F7H
  • HY-121118
    Coronaridine
    Inhibitor 99.72%
    Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression.
    Coronaridine
  • HY-162314
    TNIK-IN-8
    Inhibitor 99.58%
    TNIK-IN-8 (Compound 35b) is a potent, orally active TNKI inhibitor with a IC50 value of 6 nM. TNIK-IN-8 has antitumor activity.
    TNIK-IN-8
  • HY-N3181
    Nodosin
    Inhibitor 98.61%
    Nodosin is an orally active diterpenoid compound that can be isolated from Isodon serra. Nodosin can inhibit the proliferation and induce cell cycle arrest and apoptosis of tumor cells. Nodosin can also inhibit oxidative stress, inflammatory responses, and ferroptosis. Nodosin has anti-inflammatory and anti-tumor activities.
    Nodosin
  • HY-163513
    AACA
    Agonist 99.39%
    AACA is an inhibitor for sclerostin, that binds sclerostin on loop3 region with Kd of 15.4 nM. AACA exhibits anti-osteoporosis activity through Wnt signaling pathway.
    AACA
  • HY-10860
    WAY-362692
    Activator 99.91%
    WAY-362692 is a secreted frizzled-related protein (sFRP-1) inhibitor (IC50 of 0.02 μM), targeting the netrin domain of sFRP-1. WAY-362692 can competitively inhibit the interaction between sFRP-1 and Wnt proteins, and activate the Wnt/β-catenin signaling pathway (EC50 = 0.03 μM). WAY-362692 can activate osteoblasts and promote bone remodeling. WAY-362692 can be used for the research of metabolic disease, such as osteoporosis.
    WAY-362692
  • HY-102028
    KY1220
    98.0%
    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway, with an IC50 of 2.1 μM in HEK293 reporter cells.
    KY1220
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.